Extensior 0.25mg Injection
Available Pack Sizes
Free Shipping
Order above $200.00
Worldwide Delivery
8-10 Business Days
24/7 Support
Solve your queries
- 100% Genuine Medicines
- Secure International Logistics
- Secure Payment
- Authentic Pharmaceutical Supplier
How to Order from Medionix Pharma
Add Products
Browse our medicines and add the required products to your cart.
Add Products to Cart
Order Method
Place your order easily through WhatsApp or Email support.
Choose Your Ordering Method
Share Details
Provide your delivery address and contact information.
Share Delivery & Prescription Details
Order Dispatched
Your order is packed securely and shipped worldwide.
Order Confirmation & Dispatch
Extensior 0.25mg Injection
contains Semaglutide 0.25mg per weekly dose, manufactured by Zydus — India's globally recognised pharmaceutical company. This is the initiation dose for Extensior semaglutide therapy, designed to establish GLP-1 tolerability over the first 4 weeks before advancing to therapeutic maintenance doses. Zydus's quality manufacturing ensures pharmaceutical-grade consistency and safe dose delivery.
Benefits:
- Gentle initiation dose minimising gastrointestinal side effects during the GLP-1 adaptation phase
- Establishes the metabolic and neurological groundwork for higher-dose efficacy
- Once-weekly subcutaneous injection for maximum adherence and convenience
- Manufactured by Zydus — India's internationally certified pharmaceutical leader
- Reliable entry point into the Extensior semaglutide treatment programme
How It Works:
Even at the 0.25mg initiation dose, semaglutide begins activating GLP-1 receptors in the brain and pancreas — reducing meal-driven appetite signals, initiating mild gastric emptying delay, and priming glucose-dependent insulin pathways. This sub-therapeutic dose builds receptor and gastrointestinal tolerance before escalation to full maintenance doses.
Dosage and Administration:
Inject 0.25mg subcutaneously once weekly for 4 weeks. Administer into the abdomen, thigh, or outer upper arm at any time of day with or without food. Rotate injection sites each week. After 4 weeks, advance to the 0.5mg Extensior dose as directed.
Side Effects:
Common: mild nausea, loose stools, reduced appetite, abdominal discomfort. Uncommon: headache, fatigue. Serious: pancreatitis, thyroid C-cell tumour risk (animal data), gallbladder disease.
Precautions:
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Use with caution in renal impairment. Not recommended during pregnancy or breastfeeding.
Extensior Dosage Comparison Guide
| Strength | Best For | Onset | Duration | Link |
|---|---|---|---|---|
| 0.25mg | Lower strength option | 2–4 wks | Weekly | Current |
| 0.5mg | Popular strength option | 2–4 wks | Weekly | View → |
| 1mg | Maximum strength variant | 2–4 wks | Weekly | View → |
* Always consult your doctor before changing your dosage. This information is for educational reference only.
Frequently Asked Questions
Q1: What is Extensior 0.25mg Injection used for?
Extensior 0.25mg is the initiation dose of injectable semaglutide by Zydus, used for the first 4 weeks of GLP-1 therapy to establish tolerability before escalation to the 0.5mg therapeutic maintenance dose.
Q2: Will Extensior 0.25mg cause weight loss?
At the initiation dose, weight loss is minimal. Most significant weight reduction begins after dose escalation to 0.5mg and above. The 0.25mg phase focuses on tolerability establishment rather than therapeutic weight loss.
Q3: Why is Extensior 0.25mg priced higher than some other semaglutide initiation pens?
Pricing varies between brands due to formulation, pen design, and distribution. Extensior by Zydus represents a premium-quality semaglutide initiation option with Zydus's globally certified manufacturing standards.
Q4: How does Extensior 0.25mg differ from Hepaglide 0.5mg by the same manufacturer?
Extensior 0.25mg is the starting dose for a separate branded titration schedule. It contains less semaglutide (0.25mg vs 0.5mg) and is used only for the first 4 weeks before advancing within the Extensior dose range.
Q5: Can I skip the 0.25mg initiation and start directly at 0.5mg Extensior?
Starting at 0.5mg without titration significantly increases the risk of gastrointestinal side effects (nausea, vomiting, diarrhoea). The 0.25mg initiation phase is strongly recommended and should not be skipped without prescriber guidance.
Customer Reviews
Michael K.
USA · 2 months ago
“Fast international shipping and professional packaging. Product was exactly as described. Highly recommend this supplier.”
Dr. James Wilson
USA · 1 week ago
“Excellent product quality. Arrived well-packaged with proper cold chain maintained throughout transit. Will order again.”
Priya Sharma
India · 1 month ago
“Prompt response from the team and smooth ordering process. Medicine arrived in original sealed packaging as expected.”
FirstCare Clinic
Canada · 3 months ago
“Good value for bulk procurement orders. Communication was clear and the shipment arrived within the estimated timeframe.”
Dr. Maria Santos
Australia · 3 weeks ago
“Good quality product. Shipping was fast and handled with care. Would recommend for professional hospital procurement.”
Related Products
Disclaimer
The information provided on Medionix Pharma is intended for general informational purposes only. It should not be considered as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using any medication or starting any treatment.
Medionix Pharma does not encourage self-medication. Customers are responsible for ensuring that purchases comply with local laws and prescription requirements in their country. If you have any questions or concerns regarding the content on our website, please contact us at sales@medionixpharma.com.